2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
24
Gastrointestinal
16
Genitourinary
13
Other
8
Head & Neck
7
Other hematologic neoplasm
6
Thoracic
5
Lymphoid
5
Plasma cell
4
Gynecologic
4
CNS
4
Tumor-Agnostic
2
Sarcoma
2
Other solid neoplasm
2
Endocrine
2
Other neoplasm
1
Myeloid
1
Dermatologic
1
Conditions
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Myeloproliferative Disorders
1
Motor Activity
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Cyclophosphamide
261
fludarabine phosphate
233
Azacitidine
182
fludarabine
181
Busulfan
176
Cytarabine
155
Imatinib Mesylate
152
Mycophenolic Acid
148
Tacrolimus
146
Whole-Body Irradiation
142
Peripheral Blood Stem Cell Transplantation
140
Cyclosporine
110
Antilymphocyte Serum
108
Melphalan
107
Methotrexate
105
Filgrastim
101
Decitabine
98
nilotinib
94
venetoclax
79
ruxolitinib
79
Dasatinib
68
Granulocyte Colony-Stimulating Factor
66
Stem Cell Transplantation
63
Thiotepa
60
Radiotherapy
60
thymoglobulin
52
Specimen Handling
49
Etoposide
49
Clofarabine
46
Cord Blood Stem Cell Transplantation
45
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Resistance Training
×
Myeloid
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled